Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00550628 · ClinicalTrials.gov registry record

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

A clinical trial of Colorectal Cancer and Neoplasm of Uncertain Malignant Potential, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
8
Enrollment target
1
Study location

NCT00550628: Completed study of Colorectal Cancer and Neoplasm of Uncertain Malignant Potential, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00550628 is a study of Colorectal Cancer and Neoplasm of Uncertain Malignant Potential that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00550628, a study of Colorectal Cancer and Neoplasm of Uncertain Malignant Potential, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
8 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps. PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works in determining protein and gene expression signatures in patients with premalignant polyps or colon cancer.

Conditions Studied

Colorectal Cancer Neoplasm of Uncertain Malignant Potential

Interventions

  • GENETIC gene expression analysis
  • GENETIC protein expression analysis
  • GENETIC polymerase chain reaction
  • GENETIC DNA methylation analysis
  • GENETIC fluorescence in situ hybridization

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2007-09
Est. Completion 2011-09
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00550628 record still lists

NCT00550628 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.

NCT00550628 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00550628 about?

NCT00550628 is a clinical study titled "Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer". RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps. PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works in determining protein and gene expres...

What is the current status of trial NCT00550628?

This trial is currently completed. The enrollment target is 8 participants. The study started on 2007-09. Estimated completion is 2011-09.

What conditions does trial NCT00550628 study?

This clinical trial studies the following conditions: Colorectal Cancer, Neoplasm of Uncertain Malignant Potential.

What interventions are being tested in trial NCT00550628?

The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), polymerase chain reaction (GENETIC), DNA methylation analysis (GENETIC), fluorescence in situ hybridization (GENETIC).

Who is sponsoring clinical trial NCT00550628?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00550628 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00550628's enrollment target sits among peer trials

8 374th of 381 higher than 8 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00550628, the US trial registry maintained by the National Library of Medicine. NCT00550628 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.